moverastin A: inhibits cancer cell migration; isolated from Aspergillus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 53317632 |
| CHEMBL ID | 1683663 |
| MeSH ID | M0495432 |
| Synonym |
|---|
| moverastin a |
| CHEMBL1683663 |
| bdbm50483440 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | IC50 (µMol) | 14.7000 | 0.0005 | 0.4716 | 10.0000 | AID578269 |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | IC50 (µMol) | 14.7000 | 0.0005 | 0.2177 | 2.5000 | AID578269 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID578269 | Inhibition of protein farnesyltransferase from human EC17 cells using [3H]FPP and GTP-H-Ras | 2011 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5 | Synthesis and anti-migrative evaluation of moverastin derivatives. |
| AID578270 | Cytotoxicity against human EC17 cells assessed as cell viability by trypan blue dye | 2011 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5 | Synthesis and anti-migrative evaluation of moverastin derivatives. |
| AID578271 | Antimigratory activity against human EC17 cells assessed as inhibition of migration after 24 hrs by chemotaxis cell chamber assay | 2011 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5 | Synthesis and anti-migrative evaluation of moverastin derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (40.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||